Table 2.
Characteristics of PEAR Follow-Up Study Participants during Follow-up Period.
| Characteristic at follow-up | Number of participantsa (n=40) |
|---|---|
| Drug Treatment Characteristics | |
| Duration of thiazide treatment (months), mean (SD) | 29 (19) |
| Hydrochlorothiazide treatment | 30 (75%) |
| Dose (mg), median (IQR) | 25 (25–25) |
| Chlorthalidone treatment | 10 (25%) |
| Dose (mg), median (IQR) | 25 (25-25) |
| Thiazide monotherapy | 10 (25%) |
| Beta blocker + thiazide | 12 (30%) |
| ACEI + thiazide | 13 (33%) |
| Beta blocker + ACEI + thiazide | 5 (13%) |
| Statin treatment | 9 (23%) |
| Potassium supplementation | 5 (13%) |
| SSRI treatment | 3 (8%) |
| Glycemic Characteristics | |
| HbA1c (%, (mmol/mol)), mean [SD] | 5.7 [0.4], (38.6 [4.8]) |
| 1-hour OGTT glucose (mg/dL), mean (SD)b | 157 (47) |
| 2-hour OGTT glucose (mg/dL), mean (SD)b | 132 (51) |
| OGTT AUC (mg/dL•h), mean (SD)b | 273 (74) |
| IGT (2-hour OGTT glucose 140–199 mg/dL)b | 16 (40%) |
| EGI (1-hour OGTT glucose ≥ 155 mg/dL)b | 18 (45%) |
| New onset IFGc | 6 (15%) |
SD indicates standard deviation; ACEI, Angiotensin I converting enzyme inhibitor; SSRI, selective serotonin reuptake inhibitor; IQR, interquartile range; OGTT, oral glucose tolerance test; mg/dL, milligrams per deciliter; AUC, area under the curve; IGT, impaired glucose tolerance; EGI, elevated glucose intolerance; IFG, impaired fasting glucose.
a
Represented as number (percentage) unless otherwise noted.
b
Data acquired during 2 hour oral glucose tolerance test after 75 gram glucose load
c
Number of participants with impaired fasting glucose (fasting glucose ≥100 mg/dL) at follow-up who did not have impaired fasting glucose at baseline